Martin Hosking is Head of Research at Fate Therapeutics and is responsible for overseeing and advancing the development of iPSC-derived immune cell therapies to clinical evaluation for patients with cancer and autoimmune diseases. With more than two decades of research and leadership experience spread across academia and biotechnology, Dr. Hosking has co-authored numerous studies and patents related to the generation, regulation, and maintenance of immune cell responses to cancer and viruses. Dr. Hosking received both his Ph.D. and B.S. from the Department of Molecular Biology and Biochemistry, Biological Sciences at the University of California, Irvine.